SCHEMBL1745171

SCHEMBL1745171

COC(=O)CCc1ccc(OCc2cccc(Oc3c(C)cccc3C)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 19/20 0.79
FFAR4 Q5NUL3 5/20 0.59
VDR P11473 1/20 0.50
PPARD Q03181 1/20 0.50
AKR1B1 P15121 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747389 0.89 FFAR1 (0.80) FFAR1FFAR4VDRPPARDAKR1B1
SCHEMBL1745528 0.88 FFAR1 (1.00) FFAR1FFAR4AKR1B1
SCHEMBL1747455 0.87 FFAR1 (0.79) FFAR1FFAR4VDRPPARDAKR1B1
SCHEMBL1746701 0.87 FFAR1 (0.79) FFAR1FFAR4VDRPPARDAKR1B1
SCHEMBL1744569 0.87 FFAR1 (0.77) FFAR1FFAR4AKR1B1
SCHEMBL1745369 0.84 FFAR1 (0.76) FFAR1FFAR4AKR1B1
SCHEMBL1747205 0.83 FFAR1 (0.79) FFAR1FFAR4
SCHEMBL1744946 0.83 FFAR1 (0.56) FFAR1FFAR4VDRPPARDAKR1B1
SCHEMBL1747422 0.81 FFAR1 (0.78) FFAR1FFAR4AKR1B1
SCHEMBL1744990 0.81 FFAR1 (0.58) FFAR1FFAR4VDRPPARDAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885VDR 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.